PuSH - Publikationsserver des Helmholtz Zentrums München

24 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
1.
Scholz, S.* et al.: The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine 37, 1692-1701 (2019)
2.
Ghasemi, A.* et al.: Immunization with a recombinant fusion protein protects mice against Helicobacter pylori infection. Vaccine 36, 5124-5132 (2018)
3.
Beyerlein, A. et al.: Vaccinations in early life are not associated with development of islet autoimmunity in type 1 diabetes high-risk children: Results from prospective cohort data. Vaccine 35, 1735-1741 (2017)
4.
Link, E.K.* et al.: A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells. Vaccine 35, 5131-5139 (2017)
5.
Backes, S. et al.: Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice. Vaccine 34, 923-932 (2016)
6.
Ghasemi, A.* ; Jeddi-Tehrani, M.* ; Mautner, J. ; Salari, M.H.* & Zarnani, A.H.*: Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection. Vaccine 33, 5532-5538 (2015)
7.
Ghasemi, A.* ; Jeddi-Tehrani, M.* ; Mautner, J. ; Salari, M.H.* & Zarnani, A.H.*: Immunization of mice with a novel recombinant molecular chaperon confers protection against Brucella melitensis infection. Vaccine 32, 6659-6666 (2014)
8.
von Sonnenburg, F.* et al.: Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis. Vaccine 32, 5696-5702 (2014)
9.
Buchmann, P.* et al.: A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in Hepatitis B Virus (HBV) transgenic mice. Vaccine 31, 1197-1203 (2013)
10.
Farag, M.M.S.* et al.: Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp. Vaccine 30, 6034-6039 (2012)
11.
Schlosser, E.* et al.: TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 26, 1626-1637 (2008)
12.
Schulze, K.* et al.: A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. Vaccine 26, 6678-6684 (2008)
13.
Antonis, A.F.G.* et al.: Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 25, 4818-4827 (2007)
14.
El-Gogo, S.* et al.: Recombinant murine gammaherpesvirus 68 (MHV-68) as challenge virus to test efficacy of vaccination against chronic virus infections in the mouse model. Vaccine 25, 3934-3945 (2007)
15.
Meyer, P. et al.: Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine 24, 5832-5838 (2006)
16.
Menzel, M.* ; Muellinger, B.* ; Weber, N. ; Häussinger, K. & Ziegler-Heitbrock, L.: Inhalative vaccination with pneumococcal polysaccharide in healthy volunteers. Vaccine 23, 5113-5119 (2005)
17.
Olszewska, W.* ; Suezer, Y. & Openshaw, P.J.M.*: Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 23, 215-221 (2004)
18.
Welte, R. et al.: Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine 23, 470-479 (2004)
19.
Cosma, A. et al.: Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22, 21-29 (2003)
20.
Stittelaar, K.J.* et al.: Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 20, 2921-2927 (2002)